Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

This multinational, randomized, single-blind trial investigated the safety and efficacy of nonacog beta pegol, a recombinant glycoPEGylated factor IX (FIX) with extended half-life, in 74 previously treated patients with hemophilia B (FIX activity ≤2 IU/dL). Patients received prophylaxis for 52 weeks...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Collins, Peter W., Young, Guy, Knobe, Karin, Karim, Faraizah Abdul, Angchaisuksiri, Pantep, Banner, Claus, Gürsel, Türkiz, Mahlangu, Johnny, Matsushita, Tadashi, Mauser-Bunschoten, Eveline P., Oldenburg, Johannes, Walsh, Christopher E., Negrier, Claude
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271178/
https://ncbi.nlm.nih.gov/pubmed/25261199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-573055
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados